Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Top Cited Papers
Open Access
- 24 September 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (13), 2764-2773
- https://doi.org/10.1182/blood-2009-02-203547
Abstract
Sequential administration of DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors has demonstrated clinical efficacy inKeywords
This publication has 43 references indexed in Scilit:
- Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemiaBlood, 2008
- p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damageOncogene, 2008
- DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3BMolecular and Cellular Biology, 2008
- DNA Methyltransferase Inhibitors for Cancer TherapyThe Cancer Journal, 2007
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood, 2006
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- DNA methylation and gene silencing in cancerNature Clinical Practice Oncology, 2005
- Innovative Approaches to the Clinical Development of DNA Methylation Inhibitors as Epigenetic Remodeling DrugsSeminars in Oncology, 2005
- 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?Blood, 2003
- DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature, 2003